Intellia Therapeutics Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$92.00 | Nrq | Ncjczwv |
Intellia Earnings: Early-Stage Gene Editing Pipeline Makes Progress; Shares Very Undervalued
Intellia Therapeutics’ gene editing pipeline continues to make progress. We like that Regeneron extended its technology collaboration with the company to April 2026; Intellia will receive a $30 million payment in April 2024 as part of that extension. Intellia and Regeneron are developing in vivo Crispr-based gene editing therapies focused on neurological and muscular diseases, a collaboration that will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus vectors and delivery systems and Intellia’s proprietary Crispr/Cas9 systems adapted for viral vector delivery and designed to precisely modify a target gene.